Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Histology-driven chemotherapy of soft-tissue sarcoma.

Eriksson, Mikael LU orcid (2010) In Annals of Oncology 21. p.270-276
Abstract
Soft-tissue sarcomas are rare diseases with >50 subtypes. Surgery is the most important treatment in localized disease, sometimes combined with radiotherapy. Chemotherapy is used as palliation in advanced disease, sometimes also with a potential to decrease tumour size and eradicate micro-metastases, making meaningful surgery possible. The role of chemotherapy as adjuvant treatment in localized disease is not finally settled. Doxorubicin and ifosfamide are the two drugs with the best established response rates in soft-tissue sarcoma, and a combination of these drugs has been a 'gold standard' for several years. However, there is an emerging knowledge of the biology and sensitivity to treatment for different histological subtypes. New... (More)
Soft-tissue sarcomas are rare diseases with >50 subtypes. Surgery is the most important treatment in localized disease, sometimes combined with radiotherapy. Chemotherapy is used as palliation in advanced disease, sometimes also with a potential to decrease tumour size and eradicate micro-metastases, making meaningful surgery possible. The role of chemotherapy as adjuvant treatment in localized disease is not finally settled. Doxorubicin and ifosfamide are the two drugs with the best established response rates in soft-tissue sarcoma, and a combination of these drugs has been a 'gold standard' for several years. However, there is an emerging knowledge of the biology and sensitivity to treatment for different histological subtypes. New drugs such as gemcitabine, taxanes and trabectedin have been explored in several studies, showing promising results. Even if most studies have encompassed many different subtypes and were limited in size, knowledge related to specific treatment for different subtypes is emerging. Examples are trabectedin in liposacoma and leiomyosarcoma, and taxanes in angiosarcoma. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Chapter in Book/Report/Conference proceeding
publication status
published
subject
host publication
Educational Book of the 35th ESMO Congress Milan, Italy, 8-12 October 2010
series title
Annals of Oncology
volume
21
edition
Suppl 7
pages
270 - 276
external identifiers
  • wos:000283099200038
  • pmid:20943627
  • scopus:78649391724
ISSN
1569-8041
DOI
10.1093/annonc/mdq285
language
English
LU publication?
yes
id
2d279b0c-d4fc-4e77-b60f-9372ead13751 (old id 1711211)
date added to LUP
2016-04-04 09:29:06
date last changed
2022-02-16 02:58:59
@inproceedings{2d279b0c-d4fc-4e77-b60f-9372ead13751,
  abstract     = {{Soft-tissue sarcomas are rare diseases with >50 subtypes. Surgery is the most important treatment in localized disease, sometimes combined with radiotherapy. Chemotherapy is used as palliation in advanced disease, sometimes also with a potential to decrease tumour size and eradicate micro-metastases, making meaningful surgery possible. The role of chemotherapy as adjuvant treatment in localized disease is not finally settled. Doxorubicin and ifosfamide are the two drugs with the best established response rates in soft-tissue sarcoma, and a combination of these drugs has been a 'gold standard' for several years. However, there is an emerging knowledge of the biology and sensitivity to treatment for different histological subtypes. New drugs such as gemcitabine, taxanes and trabectedin have been explored in several studies, showing promising results. Even if most studies have encompassed many different subtypes and were limited in size, knowledge related to specific treatment for different subtypes is emerging. Examples are trabectedin in liposacoma and leiomyosarcoma, and taxanes in angiosarcoma.}},
  author       = {{Eriksson, Mikael}},
  booktitle    = {{Educational Book of the 35th ESMO Congress Milan, Italy, 8-12 October 2010}},
  issn         = {{1569-8041}},
  language     = {{eng}},
  pages        = {{270--276}},
  series       = {{Annals of Oncology}},
  title        = {{Histology-driven chemotherapy of soft-tissue sarcoma.}},
  url          = {{http://dx.doi.org/10.1093/annonc/mdq285}},
  doi          = {{10.1093/annonc/mdq285}},
  volume       = {{21}},
  year         = {{2010}},
}